NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-188-2015-0-US-04 POLYMER ADJUVANT US National Stage 15/517,121 Abandoned
NCI E-234-2014-1-HK-12 METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF HK CN 17103358.1 Pending
NCI E-161-2010-0-AU-08 PROGNOSTIC MARKERS AND METHODS FOR PROSTATE CANCER AU DIV 2017202171 Abandoned
NIAID E-128-2016-0-EP-03 MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES EP National Stage 17718216.9 Issued
NIMH E-252-2014-0-US-03 Magnetic Resonance Magnification Imaging US National Stage 15/516,339 10698056 Issued PDF
NIAID E-076-2015-4-KR-13 METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION KR National Stage 10-2017-7008911 Issued
NIAID E-128-2016-0-PCT-02 MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES PCT PCT PCT/US2017/025623 Expired
NCI E-083-2016-0-PCT-02 EXTRACELLULAR VESICLES, METHODS OF MAKING THEM, AND METHODS OF
REDUCING LIVER UPTAKE OF EXTRACELLULAR VESICLES 		PCT PCT PCT/US17/025550 Abandoned
NCI E-173-2012-2-US-04 Use of PDL1 Expressing Cells to Convert T Cells into Regulatory Cells US DIV 15/476,476 Pending
NCATS E-018-2015-0-US-05 Compositions and Methods for Inhibiting BMP US National Stage 15/516,273 Abandoned
NCATS E-018-2015-0-JP-03 2-substituted Pyridines And Their Methods For Inhibiting BMP Signaling JP National Stage 2017-538161 Pending
NIAID E-128-2016-0-SA-04 MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES SA National Stage 518400172 Pending
NIAID E-288-2016-0-PCT-02 BIOMARKERS AND IMMUNOGENIC COMPOSITIONS FOR FILARIAL PARASITES PCT PCT PCT/US17/025554 Expired
NCI E-233-2014-0-CA-03 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation CA National Stage 2963362 Pending
NCI E-289-2011-0-JP-18 YEAST-MUC1 IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF JP DIV 2017-067243 Issued
NIAID E-004-2009-2-CN-16 Viral Like Particle Compositions and Methods of Use CN DIV 201710200081.3 Pending
NIAID E-064-2016-1-CN-04 RSV F IMMUNOGENS AND THEIR USE CN National Stage 201780021719.5 Issued
NIAID E-064-2016-1-PCT-01 RSV F IMMUNOGENS AND THEIR USE PCT PCT COMB PCT/US2017/024714 Expired
NIAID E-064-2016-1-EP-05 RSV F IMMUNOGENS AND THEIR USE EP National Stage 17720590.3 Pending
NIAID E-064-2016-1-CA-03 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE CA National Stage 3015570 Pending
NCATS E-116-2016-0-CA-04 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE CA National Stage 3018959 Issued
NCATS E-116-2016-0-JP-11 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE JP DIV 2022-041167 Issued
NCATS E-116-2016-0-CN-05 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE CN National Stage 2017800276808 Issued
NCATS E-116-2016-0-AU-03 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE AU National Stage 2017238859 Issued
NHLBI E-253-2014-0-US-04 Segmented Metallic Guidewires US National Stage 15/514,744 10695540 Issued PDF
NCATS E-116-2016-0-PCT-02 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE PCT PCT PCT/US17/024241 Expired
NCATS E-036-2016-0-PCT-02 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders PCT PCT PCT/US2017/024238 Expired
NCATS E-036-2016-0-EP-06 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders EP National Stage 17716697.2 Abandoned
NCATS E-116-2016-0-JP-07 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE JP National Stage 2018-550320 Pending
NCATS E-036-2016-0-CA-04 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders CA National Stage 3019012 Abandoned
NCATS E-036-2016-0-AU-03 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders AU National Stage 2017238858 Abandoned
NIAID E-181-2014-0-US-06 Virus-Based Expression Vectors and Use Thereof US National Stage 15/514,119 10894966 Issued PDF
NICHD E-052-2020-0-US-01 MUELLER MATRIX POLARIZATION IMAGING FOR PRETERM BIRTH ASSESSMENT US ORD 15/468,763 10791983 Issued PDF
NIAID E-188-2015-0-EP-03 POLYMER ADJUVANT EP National Stage 15781141.5 Pending
NLM E-107-2010-2-US-06 SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET -FAMILY PROTEINS US CON 15/440,826 10041938 Issued PDF
NIBIB E-225-2014-0-US-04 Resolution Enhancement for Line Scanning Excitation Microscopy Systems and Methods US National Stage 15/512,870 10247930 Issued PDF
NHLBI E-037-2011-0-US-10 Development Of A Novel HDL Based Hydrophobic Drug Delivery System Using Amphipathic Peptides US CON 15/465,363 Pending
NIAID E-145-2015-3-US-02 Substituted Phenylpyrrolecarboxamides With Therapeutic Activity In HIV US National Stage 15/512,493 10137107 Issued PDF
NCI E-250-2014-0-US-04 ANTI-CD276 ANTIBODIES (B7H3) US National Stage 15/512,000 10604582 Issued PDF
NCI E-130-2016-0-PCT-02 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT PCT PCT PCT/US2017/022783 Expired
NCI E-205-2016-0-EP-03 Nanoparticle to Target Cancer EP National Stage 17767463.7 Issued
NCI E-205-2016-0-DE-01 Nanoparticle to Target Cancer DE EP 17767463.7 Issued
NCI E-205-2016-0-FR-01 Nanoparticle to Target Cancer FR EP 17767463.7 Issued
NCI E-205-2016-0-GB-01 Nanoparticle to Target Cancer GB EP 17767463.7 Issued
NCI E-130-2011-0-HK-15 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof HK EP 17102681.1 Issued
NCI E-205-2016-0-PCT-02 Nanoparticle to Target Cancer PCT PCT PCT/US2017/022567 Expired
NCI E-229-2018-0-PCT-02 AZA-A-RING INDENOISOQUINOLINE TOPOISOMERASE I POISONS PCT PCT PCT/US2017/022389 Expired
NCI E-205-2016-0-CA-04 Nanoparticle to Target Cancer CA National Stage 3017517 Pending
NICHD E-157-2011-0-US-05 SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME US DIV 15/458,234 Abandoned
NIAID E-076-2015-4-ZA-21 METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION ZA National Stage 2017/01815 Pending